Evidence map›Paper›PMID 30865282›Full record

ArticleJAMA psychiatry2019

Association of Cohort and Individual Substance Use With Risk of Transitioning to Drug Use, Drug Use Disorder, and Remission From Disorder: Findings From the World Mental Health Surveys.

Louisa Degenhardt, Chrianna Bharat, Meyer D Glantz, Nancy A Sampson, Ali Al-Hamzawi, Jordi Alonso, Laura H Andrade, Brendan Bunting, Alfredo Cia, Giovanni de Girolamo and 26 more

Erratum issuedOpen access · bronzeAbstract read
In one paragraph

Article in JAMA psychiatry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 13 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 2 pooled it
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 34 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Incidence of psychotic disorders by birth cohort: a population-based cohort study in Ontario, Canada.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Early onset of cannabis use and violent behavior in psychosis.European psychiatry : the journal of the Association of European Psychiatrists · 2020
    Article
  12. Article
  13. Error in Author Affiliation.JAMA psychiatry · 2019
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

36 authors at 20 institutions in 22 countries.

Louisa DegenhardtNational Drug and Alcohol Research Centre, University of New South Wales, Sydney, Australia.
Chrianna BharatNational Drug and Alcohol Research Centre, University of New South Wales, Sydney, Australia.
Meyer D GlantzDepartment of Epidemiology, Services, and Prevention Research, National Institute on Drug Abuse, National Institute of Health, Bethesda, Maryland.
Nancy A SampsonDepartment of Health Care Policy, Harvard Medical School, Boston, Massachusetts.
Ali Al-HamzawiCollege of Medicine, Al-Qadisiya University, Diwaniya Governorate, Iraq.
Jordi AlonsoHealth Services Research Unit, Institut Hospital del Mar Investigacions Mèdiques, Barcelona, Spain.
Laura H AndradeSection of Psychiatric Epidemiology-Laboratórios de Investigação Médica No. 23, Institute of Psychiatry, University of São Paulo Medical School, São Paulo, Brazil.
Brendan BuntingSchool of Psychology, Ulster University, Londonderry, United Kingdom.
Alfredo CiaAnxiety Disorders Center, Buenos Aires, Argentina.
Giovanni de GirolamoIRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy.
Peter De JongeDevelopmental Psychology, Department of Psychology, Rijksuniversiteit Groningen, Groningen, Netherlands.
Koen DemyttenaereDepartment of Psychiatry, University Hospital Gasthuisberg, Katholieke Universiteit Leuven, Leuven, Belgium.
Oye GurejeDepartment of Psychiatry, University College Hospital, Ibadan, Nigeria.
Josep Maria HaroParc Sanitari Sant Joan de Déu, Centro de Investigación Biomédica en Red en Salud Mental, Universitat de Barcelona, Sant Boi de Llobregat, Barcelona, Spain.
Meredith G HarrisSchool of Public Health, The University of Queensland, Brisbane, Australia.
Yanling HeShanghai Mental Health Center, Shanghai Jiao Tong University, School of Medicine, Shanghai, China.
Hristo HinkovNational Center of Public Health and Analyses, Sofia, Bulgaria.
Aimee Nasser KaramInstitute for Development, Research, Advocacy and Applied Care, Beirut, Lebanon.
Elie G KaramDepartment of Psychiatry and Clinical Psychology, Faculty of Medicine, Balamand University, Beirut, Lebanon.
Andrzej KiejnaWrocław Medical University, Wrocław, Poland.
Viviane Kovess-MasfetyEcole des Hautes Etudes en Santé Publique, EA 4057, Paris Descartes University, Paris, France.
Victor LasebikanDepartment of Psychiatry, College of Medicine, University of Ibadan, Nigeria.
Sing LeeDepartment of Psychiatry, Chinese University of Hong Kong, Tai Po, Hong Kong.
Daphna LevinsonMental Health Services, Ministry of Health, Jerusalem, Israel.
Maria Elena Medina-MoraNational Institute of Psychiatry Ramón de la Fuente Muñiz, Mexico City, Mexico.
Zeina MneimnehSurvey Research Center, Institute for Social Research, University of Michigan, Ann Arbor, Michigan.
Fernando Navarro-MateuUnidad de Docencia, Investigación y Formación en Salud Mental, Servicio Murciano de Salud, Murcia, Spain.
Marina PiazzaUniversidad Peruana Cayetano Heredia, Lima, Peru.
José Posada-VillaColegio Mayor de Cundinamarca University, Faculty of Social Sciences, Bogota, Colombia.
Kate ScottDepartment of Psychological Medicine, University of Otago, Dunedin, New Zealand.
Dan J SteinSouth African Medical Council Research Unit on Risk and Resilience in Mental Disorders, Department of Psychiatry and Mental Health, Neuroscience Institute, University of Cape Town, Cape Town, South Africa.
Hisateru TachimoriNational Institute of Mental Health, National Center for Neurology and Psychiatry, Kodaira, Tokyo, Japan.
Nathan TintleDepartment of Mathematics, Statistics and Computer Science, Dordt College, Sioux Center, Iowa.
Yolanda TorresCenter for Excellence on Research in Mental Health, CES University, Medellín, Colombia.
Ronald C KesslerDepartment of Health Care Policy, Harvard Medical School, Boston, Massachusetts.
WHO World Mental Health Survey Collaborators
Harvard University · USUNSW Sydney · AUCentro de Investigación Biomédica en Red · ESCentro San Giovanni di Dio Fatebenefratelli · ITChinese University of Hong Kong · HKDordt University · USÉcole des Hautes Études en Santé Publique · FRInstitute for Development, Research, Advocacy and Applied Care · LBInstituto Murciano de Investigación Biosanitaria · ESInstituto Nacional de Psiquiatría Ramón de la Fuente Muñiz · MXKU Leuven · BENational Center of Neurology and Psychiatry · JPNational Center of Public Health and Analyses · BGNational Institute on Drug Abuse · USShanghai Jiao Tong University · CNSouth African Medical Research Council · ZAThe University of Queensland · AUUniversidad CES · COUniversidad Colegio Mayor de Cundinamarca · COUniversidade de São Paulo · BR

Funding

Risk Factors for Psychopathology in the WHO WMH SurveysR01MH070884 · NIMH · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI KESSLER, RONALD C · 2005 to 2009
$6.0M
Trauma, Stress, and Mental Health in South AfricaR01MH059575 · NIMH · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI WILLIAMS, DAVID R · 1998 to 2007
$2.5M
Social Role Disability and Mental-Physical Co-MorbidityR01MH069864 · NIMH · KAISER FOUNDATION HEALTH PLAN OF WASHINGTON · PI VON KORFF, MICHAEL R · 2004 to 2007
$2.2M
CROSS-NATIONAL STUDIES OF DRUG INVOLVEMENT: WMH2000R01DA016558 · NIDA · MICHIGAN STATE UNIVERSITY · PI ANTHONY, JAMES CHRISTOPHER · 2003 to 2008
$1.7M
World Mental Health Consortium Annual Meeting 2003-07R13MH066849 · NIMH · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI HEERINGA, STEVEN G · 2003 to 2007
$735k
Using existing data to understand and ameliorate risk in opioid agonist therapyR01DA044170 · NIDA · UNIVERSITY OF NEW SOUTH WALES · PI DEGENHARDT, LOUISA · 2017 to 2019
$641k
Lebanon-Epidemiology: The NCS Replication StudyR03TW006481 · FIC · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI KESSLER, RONALD C · 2004 to 2006
$142k
FIC NIH HHS R03 TW006481NIDA NIH HHS R01 DA016558NIDA NIH HHS R01 DA044170NIMH NIH HHS R01 MH059575NIMH NIH HHS R01 MH069864NIMH NIH HHS R01 MH070884NIMH NIH HHS R13 MH066849
6 · The paper itself

Abstract

Importance: Limited empirical research has examined the extent to which cohort-level prevalence of substance use is associated with the onset of drug use and transitioning into greater involvement with drug use. Objective: To use cross-national data to examine time-space variation in cohort-level drug use to assess its associations with onset and transitions across stages of drug use, abuse, dependence, and remission. Design, Setting, and Participants: The World Health Organization World Mental Health Surveys carried out cross-sectional general population surveys in 25 countries using a consistent research protocol and assessment instrument. Adults from representative household samples were interviewed face-to-face in the community in relation to drug use disorders. The surveys were conducted between 2001 and 2015. Data analysis was performed from July 2017 to July 2018. Main Outcomes and Measures: Data on timing of onset of lifetime drug use, DSM-IV drug use disorders, and remission from these disorders was assessed using the Composite International Diagnostic Interview. Associations of cohort-level alcohol prevalence and drug use prevalence were examined as factors associated with these transitions. Results: Among the 90 027 respondents (48.1% [SE, 0.2%] men; mean [SE] age, 42.1 [0.1] years), 1 in 4 (24.8% [SE, 0.2%]) reported either illicit drug use or extramedical use of prescription drugs at some point in their lifetime, but with substantial time-space variation in this prevalence. Among users, 9.1% (SE, 0.2%) met lifetime criteria for abuse, and 5.0% (SE, 0.2%) met criteria for dependence. Individuals who used 2 or more drugs had an increased risk of both abuse (odds ratio, 5.17 [95% CI, 4.66-5.73]; P < .001) and dependence (odds ratio, 5.99 [95% CI, 5.02-7.16]; P < .001) and reduced probability of remission from abuse (odds ratio, 0.86 [95% CI, 0.76-0.98]; P = .02). Birth cohort prevalence of drug use was also significantly associated with both initiation and illicit drug use transitions; for example, after controlling for individuals' experience of substance use and demographics, for each additional 10% of an individual's cohort using alcohol, a person's odds of initiating drug use increased by 28% (odds ratio, 1.28 [95% CI, 1.26-1.31]). Each 10% increase in a cohort's use of drug increased individual risk by 12% (1.12 [95% CI, 1.11-1.14]). Conclusions and Relevance: Birth cohort substance use is associated with drug use involvement beyond the outcomes of individual histories of alcohol and other drug use. This has important implications for understanding pathways into and out of problematic drug use.

Indexed as

AdolescentAdultAgedAged, 80 and overCross-Sectional StudiesDrug UsersFemaleHealth SurveysHumansMaleMarijuana SmokingMental HealthMiddle AgedPrevalenceRiskSubstance-Related Disorders

Identifiers

PMID30865282
PMCPMC6583659
OpenAlexW2921942137

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.